However, the current anti‐TNF therapy is not fully effective in all patients with IBD, and approximately 40% of patients with anti‐TNF treatment will suffer from primary failure in clinical trials,10 which calls for new therapeutic strategies. Here, TNF is linked to irritable bowel syndrome.